Peripheral targets in obesity treatment: a comprehensive update (Q38194649)

30 August 2017

1 reference

title

Peripheral targets in obesity treatment: a comprehensive update (English)

1 reference

30 August 2017

0 references

A Chatzigeorgiou

1

1 reference

30 August 2017

E Kandaraki

series ordinal

2

1 reference

30 August 2017

A G Papavassiliou

series ordinal

3

1 reference

30 August 2017

M Koutsilieris

series ordinal

4

1 reference

30 August 2017

publication date

26 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

15

1 reference

30 August 2017

issue

6

1 reference

30 August 2017

page(s)

487-503

1 reference

Lymphocytes in obesity-related adipose tissue inflammation

30 August 2017

cites work

1 reference

Macrophage infiltration into adipose tissue: initiation, propagation and remodeling.

21 January 2018

1 reference

Adipose tissue recruitment of leukocytes

21 January 2018

1 reference

Obesity is associated with macrophage accumulation in adipose tissue

21 January 2018

1 reference

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

21 January 2018

1 reference

CD40L stimulates the crosstalk between adipocytes and inflammatory cells

21 January 2018

1 reference

The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance

21 January 2018

1 reference

Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome

21 January 2018

1 reference

Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.

21 January 2018

1 reference

Anti-Obesity Drugs: A Review about Their Effects and Safety

21 January 2018

1 reference

Experimental obesity, dietary-induced thermogenesis, and their clinical implications

21 January 2018

1 reference

Current and future drug targets in weight management

21 January 2018

1 reference

Pancreatic lipase inhibitors from natural sources: unexplored potential

21 January 2018

1 reference

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).

21 January 2018

1 reference

Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

21 January 2018

1 reference

Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism

21 January 2018

1 reference

Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice

21 January 2018

1 reference

Catalytic properties of MGAT3, a putative triacylgycerol synthase.

21 January 2018

1 reference

Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding.

21 January 2018

1 reference

Acylation of acylglycerols by acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption

21 January 2018

1 reference

Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1.

21 January 2018

1 reference

Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor

21 January 2018

1 reference

Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism

21 January 2018

1 reference

New approaches to target microsomal triglyceride transfer protein

21 January 2018

1 reference

Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis

21 January 2018

1 reference

CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans

21 January 2018

1 reference

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

21 January 2018

1 reference

SGLT inhibitors: a novel target for diabetes.

21 January 2018

1 reference

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

21 January 2018

1 reference

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment

21 January 2018

1 reference

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats

21 January 2018

1 reference

Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2

21 January 2018

1 reference

Targeting thermogenesis and related pathways in anti-obesity drug discovery

21 January 2018

1 reference

The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1

21 January 2018

1 reference

Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity

21 January 2018

1 reference

Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis

21 January 2018

1 reference

Microbial ecology: human gut microbes associated with obesity

21 January 2018

1 reference

Vancomycin treatment of infective endocarditis is linked with recently acquired obesity

21 January 2018

1 reference

An obesity-associated gut microbiome with increased capacity for energy harvest

21 January 2018

1 reference

A gut feeling for obesity: 7TM sensors on enteroendocrine cells

21 January 2018

1 reference

Cellular bioenergetics as a target for obesity therapy

21 January 2018

1 reference

Brown fat as a therapy for obesity and diabetes

21 January 2018

1 reference

Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes

21 January 2018

1 reference

Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia

21 January 2018

1 reference

Lipid lowering with thyroid hormone and thyromimetics

21 January 2018

1 reference

Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?

21 January 2018

1 reference

Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.

21 January 2018

1 reference

Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability

21 January 2018

1 reference

Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats.

21 January 2018

1 reference

Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine

21 January 2018

1 reference

The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans

21 January 2018

1 reference

Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion

21 January 2018

1 reference

Central and peripheral molecular targets for antiobesity pharmacotherapy

21 January 2018

1 reference

Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity

21 January 2018

1 reference

Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target

21 January 2018

1 reference

Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice

21 January 2018

1 reference

Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease

21 January 2018

1 reference

Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice

21 January 2018

1 reference

11 beta-hydroxysteroid dehydrogenase type 1 induction in the arcuate nucleus by high-fat feeding: A novel constraint to hyperphagia?

21 January 2018

1 reference

Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.

21 January 2018

1 reference

Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains

21 January 2018

1 reference

11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

21 January 2018

1 reference

2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice

21 January 2018

1 reference

11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?

21 January 2018

1 reference

Respective degree of expression of beta 1-, beta 2- and beta 3-adrenoceptors in human brown and white adipose tissues

21 January 2018

1 reference

Drug treatment of obesity: established and emerging therapies

21 January 2018

1 reference

Learning new tricks from old dogs: beta-adrenergic receptors teach new lessons on firing up adipose tissue metabolism

21 January 2018

1 reference

Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study.

21 January 2018

1 reference

Antiobesity effect of diazoxide in obese Zucker rats

21 January 2018

1 reference

No effect of inhibition of insulin secretion by diazoxide on weight loss in hyperinsulinaemic obese subjects during an 8-week weight-loss diet

21 January 2018

1 reference

Sirtuins regulate key aspects of lipid metabolism

21 January 2018

1 reference

Sirt1 protects against high-fat diet-induced metabolic damage

21 January 2018

1 reference

SirT1 regulates adipose tissue inflammation

21 January 2018

1 reference

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha

21 January 2018

1 reference

Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice

21 January 2018

1 reference

Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators

21 January 2018

1 reference

Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation

21 January 2018

1 reference

Sirtuin 1 and sirtuin 3: physiological modulators of metabolism

21 January 2018

1 reference

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

21 January 2018

1 reference

A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers

21 January 2018

1 reference

21 January 2018

Angiogenesis and obesity

1 reference

Adipose tissue mass can be regulated through the vasculature

21 January 2018

1 reference

Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice

21 January 2018

1 reference

Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732.

21 January 2018

1 reference

Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance.

21 January 2018

1 reference

Dichotomous effects of VEGF-A on adipose tissue dysfunction.

21 January 2018

1 reference

TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders

21 January 2018

1 reference

The bile acid membrane receptor TGR5: a valuable metabolic target

21 January 2018

1 reference

The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation

21 January 2018

1 reference

TGR5-mediated bile acid sensing controls glucose homeostasis

21 January 2018

1 reference

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

21 January 2018

1 reference

Targeting bile-acid signalling for metabolic diseases

21 January 2018

1 reference

Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.

21 January 2018

1 reference

Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.

21 January 2018

1 reference

New and emerging drug molecules against obesity.

21 January 2018

1 reference

Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity

21 January 2018

1 reference

CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs

21 January 2018

1 reference

Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists

21 January 2018

1 reference

Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders

21 January 2018

1 reference

Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity

21 January 2018

1 reference

Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.

21 January 2018

1 reference

Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides

21 January 2018

1 reference

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia

21 January 2018

1 reference

Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

21 January 2018

1 reference

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications

21 January 2018

1 reference

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

21 January 2018

1 reference

Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids.

21 January 2018

1 reference

Role of leptin in the regulation of glucagon-like peptide-1 secretion

21 January 2018

1 reference

Weight beneficial treatments for type 2 diabetes

21 January 2018

1 reference

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes

21 January 2018

1 reference

The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial

21 January 2018

1 reference

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Incretin-based therapies: focus on effects beyond glycemic control alone

21 January 2018

1 reference

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential

21 January 2018

1 reference

Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies

21 January 2018

1 reference

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

21 January 2018

1 reference

Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.

21 January 2018

1 reference

New pharmacological approaches for obesity management.

21 January 2018

1 reference

Reducing the risk of obesity: defining the role of weight loss drugs

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/OBR.12163

1 reference

30 August 2017

1 reference